Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.63 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.63 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.63 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.63 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.63 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.63 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.63 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.63 |
| ▸ | CCR3 | P51677 | 2/20 | 0.61 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.60 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.60 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.60 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.60 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18657232 | 0.91 | GAA (0.58) | GAAGRIN2BGRIN2DGRIN3BADRA1D | |
| SCHEMBL4023997 | 0.87 | GRIN2B (0.66) | GAAGRIN2BGRIN2DGRIN3BADRA1D | |
| Hydrochloric Acid SCHEMBL1373308 | 0.86 | GRIN2D (0.64) | GRIN2BGRIN2DGRIN3BADRA1DADRA1A | |
| SCHEMBL3867284 | 0.85 | PRMT3 (0.66) | GAACCR3PRMT3CARM1PRMT6 | |
| SCHEMBL15857848 | 0.84 | GRIN1 (0.63) | GRIN2BGRIN2DGRIN3BADRA1DADRA1A | |
| SCHEMBL10041812 | 0.84 | MEN1 (0.64) | GAAGRIN2BGRIN2DGRIN3BADRA1D | |
| Lithium Ion SCHEMBL25243064 | 0.83 | GRIN2D (0.61) | GRIN2BGRIN2DGRIN3BADRA1DADRA1A | |
| SCHEMBL5888792 | 0.82 | HTR7 (0.68) | CCR3PRMT3CARM1PRMT6PRMT1 | |
| SCHEMBL12466880 | 0.81 | MEN1 (0.64) | GAAMEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL5233388 | 0.80 | MEN1 (0.61) | GAAGRIN2BGRIN2DGRIN3BADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643960-B2 | Procaspase activating compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643960-B2 | Procaspase activating compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-09 | — | — | US | disclosed |
| EP-2393794-B1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | UNIV ILLINOIS (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20150344452-A1 | PROCASPASE ACTIVATING COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344452-A1 | PROCASPASE ACTIVATING COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-12-03 | — | — | US | disclosed |
| US-9102661-B2 | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs | THE BOARD OF TRUSTEES OF THE UNIVERSITY ILLINOIS (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102661-B2 | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs | THE BOARD OF TRUSTEES OF THE UNIVERSITY ILLINOIS (US) | 2015-08-11 | — | — | US | disclosed |
| EP-2300010-B1 | PYRAZINE DERIVATIVES AS EPITHELIAL SODIUM CHANNEL BLOCKERS | NOVARTIS AG (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-20140315915-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315915-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-10-23 | — | — | US | disclosed |
| US-8778945-B2 | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778945-B2 | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-07-15 | — | — | US | disclosed |
| US-8236808-B2 | Pyrazine derivatives as ENAC blockers | NOVARTIS AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-20120040995-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040995-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-02-16 | — | — | US | disclosed |
| CN-102112130-A | Pyrazine derivatives as epithelial sodium channel blockers | NOVARTIS AG | 2011-06-29 | — | — | CN | disclosed |
| WO-2010091382-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2009150137-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344452-A1 | PROCASPASE ACTIVATING COMPOUNDS | CASP3, CASP6, BAX | GAA 507/4885GRIN2B 2636/4885GRIN2D 3321/4885 |
| US-20140315915-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | CASP3, CASP6, CASP14 | GAA 660/4885GRIN2B 2730/4885GRIN2D 2273/4885 |
| US-20120040995-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | CASP3, CASP6, CASP14 | GAA 660/4885GRIN2B 2730/4885GRIN2D 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.